Vertex files for expanded use of Kalydeco; BMS pulls lots of injectable Coumadin;

@FiercePharma: Top-read FP news yesterday: Sex, bribes and videotape: Clandestine video of GSK exec adds to China scandal. Report | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: ICYMI: FDA approves Ranbaxy's generic Diovan at Indian drugmaker's Ohm plant in New Jersey. Story | Follow @EricPFierce

@CarlyHFierce: Prevnar use in seniors is cost-effective now, CDC says. But will it last? FierceVaccines story | Follow @CarlyHFierce

> Vertex Pharmaceuticals ($VRTX) asked the FDA to expand use of its cystic fibrosis drug Kalydeco, to patients with a common mutation related to the disease. Release

> Bristol-Myers Squibb ($BMY) recalled 6 lots of injectable Coumadin after finding particulate matter in a small number of unreleased samples. Report

> Federal prosecutors urged a New York judge not to dismiss False Claims Act complaints against Novartis in a case involving alleged kickbacks to pharmacies. Report (reg. req.)

> Pfizer ($PFE) persuaded a Pennsylvania federal judge to exclude an expert witness in litigation over its antidepressant Zoloft and its potential inks to birth defects. Report

> Médecins Sans Frontiéres won approval from South African officials to import a cheap generic version of the anti-tuberculosis drug linezolid to allow it to treat more patients. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Neuro-stimulator startup electroCore secures Series A expansion to $50M. Article | Follow @FierceMedDev

@StacyALawrence: Study: One-third of knee replacements are inappropriate. More | Follow @StacyALawrence

@VarunSaxena2: ICYMI yesterday: Stryker to buy Small Bone Innovations for up to $375M. Story | Follow @VarunSaxena2

@MichaelGFierce: Nanoparticles designed to prevent cancer, aid bones. More | Follow @MichaelGFierce

@EmilyWFierce: GPS tracking devices used to prevent injuries in U.S. Men's National Soccer Team players. Bloomberg story | Follow @EmilyWFierce

> Report: $2.3B in digital health venture financing in the first half. Item

> FDA clears 3D virtual reality device for surgical procedures. News

> In obesity device race, ReShape lines up with FDA. More

Biotech News

@FierceBiotech: 's gaze puts the brakes on 's plans for major M&A. ICYMI yesterday | Follow @FierceBiotech

@JohnCFierce: Biotech IPO scorecard: Hits, runs and errors mount in 9th inning frenzy (it's getting crazy out there). Report | Follow @JohnCFierce

@DamianFierce: A truly disruptive, outcomes-driven look at biotech's new nonsense. Xconomy piece | Follow @DamianFierce

@EmilyMFierce: ICYMI: Experimental heart disease vaccine lowers plaque in mice arteries. FierceBiotech Research article | Follow @EmilyMFierce

> Agenus spikes on positive data for its brain cancer vaccine. Story

> Sanofi bumps stake in Regeneron to 22.5%. Item

> Paratek absorbs the troubled Transcept in a reverse merger. Article

> Angling for early OK, Amgen wins 'breakthrough' title for leukemia drug. News

> Bluebird bio snares gene-editing tech in $156M buyout deal. Report

Biotech Research News

> New antibiotic may combat drug-resistant tuberculosis. Story

> Enzyme inhibitor could curb post-stroke injury. More

> Alzheimer's compound targets abnormal blood clots in brain. Story

> Experimental heart disease vaccine lowers arterial plaque in mice. Article

> Pfizer to partner with South African university on preclinical research. Item

Pharma Manufacturing News

> Teva growth hormone for children recalled after oil leaks into product. News

> Manufacturing questions lead to another CRL for Allergan migraine drug. Report

> Janssen will stop making antibiotic Levaquin. Item

> India's IPA hires consulting firm to help it overcome bad publicity. News

> Cipla buys capacity in Yemen with deal to control company there. Article

> FDA OKs Ranbaxy New Jersey plant to make generic Diovan. Story

And Finally... Stress is literally a killer in China, where about 600,000 people--including those in their twenties--die each year from working too hard. Report